<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US5792795 - Treatment of inflammatory bowel disease using oral dosage forms of omega-3 ... - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_4ff636b3d23669b7103f3b3a3a18b4cd/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_4ff636b3d23669b7103f3b3a3a18b4cd__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids"><meta name="DC.contributor" content="Thomas Buser" scheme="inventor"><meta name="DC.contributor" content="Emilio P. Camporesi" scheme="inventor"><meta name="DC.contributor" content="Tillotts Pharma Ag" scheme="assignee"><meta name="DC.date" content="1996-5-13" scheme="dateSubmitted"><meta name="DC.description" content="Inflammatory bowel disease, especially Crohn&#39;s disease and ulcerative colitis, is treated by administration of an oral dosage form, containing as an active principle an omega-3 polyunsaturated acid in free acid form or as a pharmaceutically acceptable salt thereof, which releases the acid in the ileum. Preferably the oral dosage form is a gelatine capsule coated with a poly(ethylacrylate-methylmethacrylate)."><meta name="DC.date" content="1998-8-11" scheme="issued"><meta name="DC.relation" content="EP:0225303:A1" scheme="references"><meta name="DC.relation" content="EP:0289204:A2" scheme="references"><meta name="DC.relation" content="GB:2223943" scheme="references"><meta name="DC.relation" content="US:5252333" scheme="references"><meta name="DC.relation" content="US:5411988" scheme="references"><meta name="DC.relation" content="US:5422115" scheme="references"><meta name="DC.relation" content="US:5603953" scheme="references"><meta name="citation_reference" content="Belluzzi, A., et al, abstract titled &quot;New Fish Oil Derivative for Preventing Clinical Relapses in Crohn&#39;s Disease: A Double Blind Placebo Controlled Randomized Trail&quot;, published Digestive Disease Weekly 14 May 1995."><meta name="citation_reference" content="Belluzzi, A., et al, abstract titled New Fish Oil Derivative for Preventing Clinical Relapses in Crohn s Disease: A Double Blind Placebo Controlled Randomized Trail , published Digestive Disease Weekly 14 May 1995."><meta name="citation_reference" content="Rohm Pharma Gmbh brochure titled &quot;Sustained-release coatings with EudragitÂ® NE 30D from aqueous dispersions&quot; (1995)."><meta name="citation_reference" content="Rohm Pharma Gmbh brochure titled Sustained release coatings with Eudragit NE 30D from aqueous dispersions (1995)."><meta name="citation_patent_number" content="US:5792795"><meta name="citation_patent_application_number" content="US:08/687,329"><link rel="canonical" href="http://www.google.com/patents/US5792795"/><meta property="og:url" content="http://www.google.com/patents/US5792795"/><meta name="title" content="Patent US5792795 - Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids"/><meta name="description" content="Inflammatory bowel disease, especially Crohn&#39;s disease and ulcerative colitis, is treated by administration of an oral dosage form, containing as an active principle an omega-3 polyunsaturated acid in free acid form or as a pharmaceutically acceptable salt thereof, which releases the acid in the ileum. Preferably the oral dosage form is a gelatine capsule coated with a poly(ethylacrylate-methylmethacrylate)."/><meta property="og:title" content="Patent US5792795 - Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("ceToU-WoFdS2yASH9oI4"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407291699.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("LUX"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("ceToU-WoFdS2yASH9oI4"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407291699.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("LUX"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us5792795?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US5792795"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=EJdHBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS5792795&amp;usg=AFQjCNHlZ66RA72KzRz1FZCtJ592ioFs2g" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US5792795.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US5792795.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US5792795" style="display:none"><span itemprop="description">Inflammatory bowel disease, especially Crohn&#39;s disease and ulcerative colitis, is treated by administration of an oral dosage form, containing as an active principle an omega-3 polyunsaturated acid in free acid form or as a pharmaceutically acceptable salt thereof, which releases the acid in the ileum....</span><span itemprop="url">http://www.google.com/patents/US5792795?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US5792795 - Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US5792795 - Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids" title="Patent US5792795 - Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US5792795 A</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 08/687,329</td></tr><tr><td class="patent-bibdata-heading">PCT number</td><td class="single-patent-bibdata">PCT/EP1996/002038</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Aug 11, 1998</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">May 13, 1996</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">May 15, 1995</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2221356A1">CA2221356A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CA2221356C">CA2221356C</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1104237C">CN1104237C</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1184421A">CN1184421A</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69634693D1">DE69634693D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69634693T2">DE69634693T2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0825858A1">EP0825858A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0825858B1">EP0825858B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5948818">US5948818</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO1996036329A1">WO1996036329A1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">08687329, </span><span class="patent-bibdata-value">687329, </span><span class="patent-bibdata-value">PCT/1996/2038, </span><span class="patent-bibdata-value">PCT/EP/1996/002038, </span><span class="patent-bibdata-value">PCT/EP/1996/02038, </span><span class="patent-bibdata-value">PCT/EP/96/002038, </span><span class="patent-bibdata-value">PCT/EP/96/02038, </span><span class="patent-bibdata-value">PCT/EP1996/002038, </span><span class="patent-bibdata-value">PCT/EP1996/02038, </span><span class="patent-bibdata-value">PCT/EP1996002038, </span><span class="patent-bibdata-value">PCT/EP199602038, </span><span class="patent-bibdata-value">PCT/EP96/002038, </span><span class="patent-bibdata-value">PCT/EP96/02038, </span><span class="patent-bibdata-value">PCT/EP96002038, </span><span class="patent-bibdata-value">PCT/EP9602038, </span><span class="patent-bibdata-value">US 5792795 A, </span><span class="patent-bibdata-value">US 5792795A, </span><span class="patent-bibdata-value">US-A-5792795, </span><span class="patent-bibdata-value">US5792795 A, </span><span class="patent-bibdata-value">US5792795A</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Thomas+Buser%22">Thomas Buser</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Emilio+P.+Camporesi%22">Emilio P. Camporesi</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Tillotts+Pharma+Ag%22">Tillotts Pharma Ag</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US5792795.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5792795.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5792795.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (7),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (4),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (18),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (14),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (7)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=EJdHBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/5792795&usg=AFQjCNFapkvuMB6ytdKWKXHcAdqRUumomA">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=EJdHBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D5792795&usg=AFQjCNG_kl75ZUSyYZfBXOCmzD1CWof1DQ">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=EJdHBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D5792795A%26KC%3DA%26FT%3DD&usg=AFQjCNEF6a_q3X8fCSOg_TXjHdlA3rbkMw">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT54336227" lang="EN" load-source="patent-office">Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids</invention-title></span><br><span class="patent-number">US 5792795 A</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA37802403" lang="EN" load-source="patent-office"> <div class="abstract">Inflammatory bowel disease, especially Crohn's disease and ulcerative colitis, is treated by administration of an oral dosage form, containing as an active principle an omega-3 polyunsaturated acid in free acid form or as a pharmaceutically acceptable salt thereof, which releases the acid in the ileum. Preferably the oral dosage form is a gelatine capsule coated with a poly(ethylacrylate-methylmethacrylate).</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(5)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5792795-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5792795-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5792795-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5792795-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5792795-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5792795-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5792795-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5792795-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5792795-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5792795-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(17)</span></span></div><div class="patent-text"><div mxw-id="PCLM5269153" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>We claim:</claim-statement> <div class="claim"> <div num="1" class="claim">
      <div class="claim-text">1. An oral dosage form for treating inflammatory bowel disease, containing an active compound selected from the group consisting of omega-3 polyunsaturated acids and pharmaceutically acceptable salts thereof and containing a neutral polyacrylate coating which is resistant to release of the active compound for a period of 30 to 60 minutes at pH 5.5 whereby the active compound is released in the ileum.</div>
    </div>
    </div> <div class="claim"> <div num="2" class="claim">
      <div class="claim-text">2. An oral dosage form comprising a coated capsule containing as an active principle an omega-3 polyunsaturated acid in free acid form or a pharmaceutically acceptable salt thereof, wherein the coating is a neutral polyacrylate whereby the active principle is released in the small intestine.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" class="claim">
      <div class="claim-text">3. An oral dosage form as claimed in claim 2 wherein the coating is resistant to release of the omega-3 polyunsaturated acid for a period of 30 to 60 minutes at pH 5.5.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" class="claim">
      <div class="claim-text">4. An oral dosage form as claimed in claim 2 wherein the coating is a poly(ethylacrylate-methylmethacrylate).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" class="claim">
      <div class="claim-text">5. An oral dosage form as claimed in claim 4 wherein the coating comprises iron oxide, titanium dioxide, and talc.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" class="claim">
      <div class="claim-text">6. An oral dosage form as claimed in claim 5 wherein the coating contains by ratio about 3 mg iron oxide, about 2.35 mg titanium dioxide, and about 10 mg talc to about 60 mg of poly(ethylacrylate-methylmethacrylate).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="7" class="claim">
      <div class="claim-text">7. An oral dosage from as claimed in claim 2 wherein said acid is eicosapenta-5,8,11,14,17-enoic acid, docosahexa--4,7,10,13,16,19-enoic acid or a mixture thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="8" class="claim">
      <div class="claim-text">8. An oral dosage form as claimed in claim 7 wherein the eicosapenta-5,8,11,14,17-enoic acid, docosahexa-4,7,10,13,16,19-enoic acid or mixture thereof is present in an oil constituent in a percentage of at least 60% w/w.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="9" class="claim">
      <div class="claim-text">9. An oral dosage form as claimed in claim 2 wherein said acid is present as the sole active principle.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="10" class="claim">
      <div class="claim-text">10. An oral dosage form as claimed in claim 2 wherein said active principle is an omega-3 polyunsaturated acid in free acid form or a pharmaceutically acceptable salt thereof except for a lithium salt thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="11" class="claim">
      <div class="claim-text">11. An oral dosage form as claimed in claim 2 wherein the capsule is a hard or soft gelatin capsule.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="12" class="claim">
      <div class="claim-text">12. An oral dosage form as claimed in claim 2 containing as an active principle a unit dose of 250 to 1,000 mg.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="13" class="claim">
      <div class="claim-text">13. A method of treating inflammatory bowel disease or reducing clinical relapse thereof, which comprises administering to a patient an effective amount of an oral dosage form as claimed in claim 2.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="14" class="claim">
      <div class="claim-text">14. A method as claimed in claim 13 wherein the inflammatory bowel disease is Crohn's disease.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="15" class="claim">
      <div class="claim-text">15. A method as claimed in claim 14 wherein patients are in clinical remission for less than 24 months prior to treatment.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="16" class="claim">
      <div class="claim-text">16. A method as claimed in claim 13 which comprises administering a daily dosage of 20 to 50 mg/kg omega-3 polyunsaturated acid.</div>
    </div>
    </div> <div class="claim"> <div num="17" class="claim">
      <div class="claim-text">17. An oral dosage form comprising a capsule containing eicosapenta-5,8,11,14,17-enoic acid, docosahexa-4,7,10,13,16,19-enoic acid or a mixture thereof, and coated with poly(ethylacrylate-methylmethacrylate).</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES67161089" lang="EN" load-source="patent-office" class="description">
    <p>This application is a 371 of PCT/EP96/02038, filed May 13, 1996.</p>
    <p>The present invention relates to the oral administration of omega-3 polyunsaturated acids especially, but not exclusively, eicosapenta-5,8,11,14,17-enoic acid ("EPA") and/or docosahexa-4,7,10,13,16,19-enioc acid ("DHA"). In particular, it provides enteric dosage forms of omega-3 polyunsaturated acids for the treatment of inflammatory bowel disease especially, but not exclusively, Crohn's disease and ulcerative colitis.</p>
    <p>It is known that DHA, EPA and other omega-3 polyunsaturated acids are of use in the treatment of inflammatory bowel disease (see, for example, EP-A-0244832, EP-A-0289204, EP-A-0311091 &amp; WO-A-93/21912).</p>
    <p>EP-A-0244832 discloses pharmaceutical compositions containing certain unsaturated fatty acids with certain specified stimulators. The compositions are of use for treating disorders associated with prostaglandin deficiency, especially gastrointestinal ulcers. The unsaturated fatty acids are those which have 3 to 5 isolated double bonds and 18 to 22 carbon atoms arranged in a straight chain and are capable of being methylated or ethylated at one or two carbon atoms in positions 2, 3, 4, 16, 17, 18, 19 or 20. EPA is amongst the exemplified acids. Reference is made to pH dependent delayed release formulations containing polystyrene or polyacrylic derivatives and to enteric coated products.</p>
    <p>EP-A-0289204 discloses disinfectant and pharmaceutical compositions comprising the lithium salt of a C<sub>18</sub> -C<sub>22</sub> polyunsaturated fatty acid. Specified polyunsaturated fatty acids include DHA and EPA. The pharmaceutical compositions can be for enteral, parenteral and topical administration and are for use in the treatment of conditions responsive to lithium and/or polyunsaturated fatty acid therapy. Specified conditions responsive to polyunsaturated fatty acid therapy include Crohn's disease and ulcerative colitis. Reference is made to providing an enteric coat of, for example, an acrylate or cellulose acetate phthalate to delay release of the salt until the intestine.</p>
    <p>EP-A-0311091 discloses physiologically acceptable isotonic fat emulsions containing an omega-3-fatty acid or ester, a medium-chain length triglyceride, and an emulsifier. The fatty acid or ester component can be present as a pure compound or in the form of a fish oil and preferably is EPA. The emulsion is administered parenterally for, inter alia, treatment of chronic inflammatory bowel disease.</p>
    <p>WO-A-93/21912 discloses the use of emulsions containing a polyunsaturated long-chain omega-3-fatty acid or ester for parenterally administration to treat inflammatory disorders including inflammatory bowel disease. The fatty acid or ester can be present as fish oil and preferred fatty acids include DHA and EPA.</p>
    <p>Enteric coated products containing DHA or EPA have been reported for use in the treatment of other conditions (see EP-A-0336662, GB-A-2090529, JP-A-62201823, &amp; WO-A-90/04391)</p>
    <p>EP-A-0336662 discloses the micro encapsulation of fish oil acids within an enteric coating to provide a stable, odorless and tasteless composition for incorporation into a food product to reduce plasma triglyceride, low density lipoprotein and cholesterol levels . The specified coating materials are ethyl cellulose, cellulose acetate phthalate and cellulose acetate trimelitate. Reference is made to release of the active below the pylorus in the upper portion of the intestine but there is no specific reference to targeting release to the ileum.</p>
    <p>GB-A-2090529 discloses the prophylaxis and treatment of thrombosis using DHA or esters or amides thereof. Reference is made in general terms to intestine soluble coated tablets and to film coated tablets.</p>
    <p>JP-A-62201823 discloses enterically coated capsules for treating enteral abnormal fermentation or diarrhoea which contain bacteria in an oil. The oil can be EPA and a number of enteric materials are specified including shellac, carboxymethyl cellulose, cellulose acetate phthalate, hydroxymethyl propylcellulose phthalate, and polyvinyl alcohol phthalate.</p>
    <p>WO-A-90/04391 (and corresponding GB-A-2223943) discloses that enteric dosage forms of EPA, DHA and other omega-3 polyunsaturated fatty acids overcome the problem of belching and flatulence associated with oral administration of these acids. The exemplified coating is cellulose acetate phthalate/ethyl phthalate but reference is made to the use of polymethacrylate as the coating material.</p>
    <p>Belluzzi et al (Dig. Dis. Sci. 39 (1994) 2589-2594) reported a study in which five groups of patients with Crohn's disease were treated with:</p>
    <p>Group A--uncoated gelatine capsules containing 500 mg "Purepa" fish oil concentrate (containing EPA 40% and DHA 20%);</p>
    <p>Group B--gelatine capsule containing 500 mg "Purepa" fish oil concentrate and coated with a pH 5.5/120 minutes or cellulose acetate trimellate ("CAT") coating;</p>
    <p>Group C--gelatine capsule containing 500 mg "Purepa" fish oil concentrate and coated with a pH 5.5/60 minutes CAT coating;</p>
    <p>Group D--gelatine capsule containing 500 mg "Purepa" fish oil concentrate and coated with a pH 6.9/120 minutes cellulose acetate phthalate ("CAP") coating; and</p>
    <p>Group E--uncoated gelatine capsule containing 1000 mg "Max-EPA" triglyceride fish oil (EPA 18% and DHA 10%).</p>
    <p>CAP dissolves at pH 6.8 and CAT dissolves at pH 5.5. All the coated capsules disintegrate within 15 minutes at the relevant pH. In the results of the Belluzzi, et al., study, the item before the slash (/) is the pH at which the coating rapidly dissolves the the item following the slash (/) is the time for which the coating is resistant to gastric juice.</p>
    <p>The four groups taking Capsule Types A to D took 9 capsules (2.7 g of omega-3 polyunsaturated acid) during meals 3 times daily for 6 weeks and those taking Type E capsules received 12 capsules (3.4 g of omega-3 poly-unsaturated acid) daily in divided doses during meals over the 6 week period.</p>
    <p>All of the five regimens increased the incorporation of the omega-3 polyunsaturated acid both in plasma and red blood cell phospholipid membranes by displacing arachidonic acid, linoleic acid, and to a lesser extent oleic acid. However, much more of the free omega-3 polyunsaturated fatty acid mixture was absorbed using the capsules containing "Purepa" fish oil concentrate than when using "Max-EPA" triglyceride mixture. The incorporation was coating dependent and it is speculated to be related to the site of capsule-disintegration. The Group C capsules (having the pH 5.5/60 minutes coating) gave the best incorporation of the omega-3 polyunsaturated fatty acids in the plasma and red blood cell phospholipid membranes. The Group D capsules (having the pH 6.9 coating) gave very poor incorporation and 70% of patients in this Group had increased daily bowel motion. Slightly better incorporation was registered with the Group B capsules (having the pH 5.5/120 minutes coating), but 50% of 5 patients in the Group reported diarrhoea.</p>
    <p>The Group C capsules used by Belluzzi et al combined both pH and time-dependent release mechanisms and made it possible to avoid capsule-breakdown (pH 5.5) in the stomach-duodenum, and consequently void upper gastrointestinal side-effects. Since they were only gastric resistant for 60 minutes, they allowed quick release of the fish oil concentrate in the small intestine and its complete absorption.</p>
    <p>Surprisingly, it has now been found that the optimum combination of absorption and absence of side effects occurs if the release of polyunsaturated fatty acid is controlled to occur in the ileum, especially mid-ileum.</p>
    <p>Thus, the present invention provides an oral dosage form, containing as an active principle an omega-3 polyunsaturated acid in free acid form or as a pharmaceutically acceptable salt thereof, which releases the acid in the ileum.</p>
    <p>The present invention also provides the use of an omega-3 polyunsaturated acid in free acid form or as a pharmaceutically acceptable salt thereof in the manufacture of a medicament releasing the acid in the ileum for the treatment of inflammatory bowel disease.</p>
    <p>Further, the present invention provides the use of said oral dosage forms in the treatment inflammatory bowel disease.</p>
    <p>It is preferred that the omega-3 polyunsaturated acid is DHA, EPA or a mixture thereof. It is present in free acid form or as a pharmaceutically acceptable salt thereof and can be present as the sole active principle or with other active principles. Suitably, a fish oil concentrate containing at least 60% by weight DHA and EPA is used.</p>
    <p>Omega-3 polyunsaturated acids are readily oxidised and hence an antioxidant usually will be present. The presently preferred antioxidant is gamma-tocopherol but other pharmacologically acceptable antioxidants can be used, for example butylated hydroxy anisole, butylated hydroxy toluene, propyl gallate or a quinone.</p>
    <p>The oral dosage form may also contain one or more pharmaceutically acceptable excipients depending upon the precise nature of the dosage form. Suitably, the oral dosage form can be a coated tablet containing the omega-3 polyunsaturated acid in a micro encapsulated form or loaded on a suitable absorbent. However, it is preferred that the oral dosage form is a coated capsule, especially a soft or, more especially, hard gelatine capsule.</p>
    <p>The coating must be such as to release the acid in the ileum, preferably in the mid-ileum. Usually, dissolution of the coating will be entirely time dependent but a coating relying on a combination of time and pH dependence can be used. Suitably, the coating is resistant for a period of 30 to 60 minutes at pH 5.5. The presently preferred coating is a neutral polyacrylate such as a poly(ethylacrylate-methylmethacrylate), especially Eudragit NE 30-D (Rohm Pharma GmbH) which has an average molecular weight of about 800,000.</p>
    <p>Usually, the omega-3 polyunsaturated acid will be administered in a daily dosage of 20 to 50 mg/kg, especially 30-40 mg/kg. The actual dose will vary depending inter alia on the identity of the omega-3 polyunsaturated acid and the nature and degree of the disorder being treated. Usually, each unit dose will contain 250 to 1000 mg, especially 400 to 800 mg.</p>
    <p>The following is a description, by way of example only, of a presently preferred embodiment of the invention.</p>
    <heading>EXAMPLE 1</heading> <p>Transparent hard gelatine capsules (Elanco Qualicaps size 0; Lilly France SA) were each filled with 500 mg of a fish oil concentrate containing at least 60% by weight DHA and EPA (Incromega 3F60; Croda Universal Ltd, UK). The filled gelatine capsules were film coated with EudragitÂ® NE 30-D to provide resistance for 30 to 60 minutes at pH 5.5 by spraying with a film coating composition (see below) at 35 ml/min using 0.8 bar pressure at 25Â° C. and air drying for at least 30 mins at 25Â° C.</p>
    <p>The film coating composition (for 50,000 capsules) was prepared by slowly adding silicon anti-foam emulsion (0.36 mg), brown iron oxide (E 172; 3.00 mg), titanium dioxide (2.35 mg) and talc (10 mg) in succession to water (75 mg) and agitating for 1 to 2 hours to form a very fine dispersion. A 30% aqueous dispersion of a poly(ethylacrylate-methylmethacrylate) having an average molecular weight of about 800,000 (EudragitÂ® NE 30D; 60 mg) and added to polysorbate 80 (MO 55 F; 0.2 mg) in a little water and the resultant mixture agitated. Silicon anti-foam emulsion (2 or 3 drops) was added to destroy the resultant foam and the aforementioned dispersion was slowly added. The vessel was washed with water (25 mg) and the dispersion stirred for 30 minutes before being filtered (150 Î¼m).</p>
    <heading>EXAMPLE 2</heading> <p>A double-blind placebo-controlled randomised study was conducted using 78 patients with well established diagnosis of Crohn's disease in clinical remission according to the Crohn's disease activity index (CDAI) and satisfying all the following criteria:</p>
    <p>(a) CDAI&lt;150 for at least 3 months but less than 2 years;</p>
    <p>(b) at least one abnormal value of alpha-1 acid glycoprotein (&gt;130 mg/d!), erythrocyte sedimentation rate (ESR);</p>
    <p>(c) (&gt;40mm/h), or alpha-2 globulin (&gt;0,9 g/dl);</p>
    <p>(d) no treatment with 5-aminosalicylate, suiphasalazine or corticosteroids in the previous 3 months, or with immunosuppressive therapy in the previous 6 months;</p>
    <p>(e) no previous bowel resection&gt;1 m; and</p>
    <p>(f) age 18-75 years.</p>
    <p>The patients were blindly randomised into two groups of 39 patients to receive daily either 9 enteric-coated hard gelatine capsules containing 500 mg of a fish oil concentrate ("Purepa"; see Table 1) or 9 enteric-coated capsules of identical appearance containing 500 mg of a placebo (MiglyolÂ® 812). The fish oil concentrate contained 40% EPA and 20% DHA. Both sets of capsule were coated with Eudragit NE 3OD to resist gastric acid or gut juice for at least 30 min and to disintegrate within 60 min at pH 5.5, allowing release of the fish oil in the small intestine. During the treatment the patients did not take any other medication. The clinical characteristics of both groups of patient are set forth in Table 2.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 1______________________________________COMPOSITION OF CAPSULE CONTENTS        Purepa (fish oil)        Free fatty acids                    Miglyol (placebo)Lipid profile        %           Neutral oil______________________________________C 14:0       --C 16:0       0.4C 16:1       3.2C 16:2       2.1C 16:3       2.4C 16:4       5.2C 18:0       --C 18:1       0.8C 18:2       1.5C 18:3       1.3C 18:4       6.9C 20:1       --C 20:3       1.5C 20:4 (AA)  1.7C 20:5 (EPA) 42.4C 21:5       1.6C 22:5       0.5C 22:6 (DHA) 19.9______________________________________</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 2______________________________________CLINICAL CHARACTERISTICS OF PATIENTS            PUREPA  PLACEBO______________________________________MALE               20        19FEMALE             19        20AGE                34 (18-67)                        39 (20-65)(years; median (range)SMOKERS            14/39     13/39DURATION OF DISEASE              68 (24-94)                        66 (20-88)(months, median (range)PREVIOUS OPERATION &lt;1 m              14/39     13/39SITE OF INVOLVEMENTileum              25        24ileum + colon      14        15CDAI median (range)              78 (28-120)                        82 (30-112)ESR     36.9            35.7(mm/h)  (SD 27-min 6;max 122)                   (SD 24-min 12;max 90)ALPHA-2 9.6             9.2globulins   (SD 1.8-min 6.1;max 13.2)                   (SD 1.3-min 6.5;max 11.9)(g/l)ALPHA-1 136.8           137.1GLYCO-  (SD 52-min 53;max 257)                   (SD 58-min 60;max 263)PROTEIN(mg/dl)______________________________________</pre>
    
    <p>Each patient in the fish oil group received 1.8 g of EPA and 0.9 g of DHA daily for 12 months. They were examined on entry to the study and at 3, 6 and 12 months or before if symptoms worsened with an increase of CDAI of at least 100 points from baseline value and above 150 for more than 2 weeks. During each visit, laboratory tests were made of blood, kidney, liver, ESR, alpha-1 acid glyco-protein, alpha-2 globulin and CRP (c-AMP-Receptor-Protein). At time 0, 6 months and at the end of the study, 2 ml of packed red cells and polymorphonuclear leucocytes were obtained following the procedure described by Popp-Snijders et al (Scan. J. Clin. Lab. Invest 44 (1984) 39-46) and their membrane lipids were extracted as described by Dodge and Phillips (J. Lipid Res. 8 (1967) 667-675) using a 2:1 mixture of chloroform and methanol containing 0.01% butylated hydroxytoluene (2,6 di-tert-butyl-p-cresol) as antioxidant. Samples were stored under nitrogen at -20Â° C. for less than 2 weeks prior to separation of the phospholipids and analysis of the omega-3 polyunsaturated fatty acids. Phospholipid fractions were obtained from the extracted lipids using 1-dimensional thin layer chromatography. The samples were spotted in one corner of a silica plate and developed with chloroform/methanol/acetic acid/water (25:14:4:2). The separated phospholipids were transmethylated using 1 N potassium hydroxide in methanol and boron trifluoride in 14% methanol for 10 min at 80Â° C. Fatty acid methyl esters were then extracted in hexane, resuspended in 100 Î¼l of benzene and analyzed by gas-chromatography equipped with a capillary column (0.32 mm i.d.Ã25 m), using helium as the carrier gas (flow rate 3ml/min) and flame ionisation detection. The column temperature was programmed between 170Â° C. and 210Â° C. at 5Â°/min with the injector and detector temperatures at 220Â° C. and 250Â° C., respectively. Individual fatty acid methyl esters were identified by comparison with commercial standards. Heptadecanoic acid (17:0) was used as the internal standard (1 mg/ml in benzene) and the results expressed as relative percentages.</p>
    <p>The difference in the relapse rate in the fish oil and placebo groups was analyzed using the chi-squared test on a `compliance only` and `intention to treat` basis. Differences between features of patients in the active and the placebo group were analyzed using the Mann-Whitney U-test, and the laboratory results were analyzed with Student's t-test for paired data (both tests 2-tailed). Kaplan-Maier life-table curves for patients remaining in remission were calculated according to the assigned treatment. Differences in the curves were tested by log rank analysis. Multiple regression analysis was performed between some variables (trial treatment, gender, age, previous surgery, length of disease) and clinical relapses; the forward procedure was used for selecting a more representative model.</p>
    <p>In the fish oil group, 1 patient withdrew (moved away) and 4 dropped out because of diarrhoea. In the placebo group, 1 patient withdrew (did not attend the outpatient clinic) and 1 dropped out because of diarrhoea. Diarrhoea started in all 5 cases within the first month of treatment and symptoms did not improve when the daily capsule intake was reduced. This diarrhoea might have been due to the delivery of the capsule contents into the distal part of the gut. The coating is time-dependent (30-60 min at pH 5.5) so if the transit time is short, the capsules would remain intact further along the intestine.</p>
    <p>The relapse rate was significantly reduced by the fish oil compared to the placebo group: chi squared 11.75; p=0.0004 (difference 41%, 95% confidence interval (Cl) 16-66). This difference was significant too on an intention to treat analysis: chi squared 9.05; p=0.0026 (difference 32%, 95% (Cl) 12-52).</p>
    <p>Table 3 summarises the clinical results and Table 4 summarises the laboratory variables of inflammation at entry and at 12 months in the patients who received the fish oil and were still in remission at the end of the study. No significant decrease in any of the laboratory findings of disease activity occurred in the placebo group. Table 5 shows the incorporation of the main fatty acids into phospholipid membranes (AA=arachidonic acid and LA=linoleic acid). Multiple regression analysis indicated that only the fish oil capsules significantly affected clinical relapse (t=3,16; p=0,002;F ratio=10; p=0,002).</p>
    <p>Over a period of 12 months the fish oil capsules used in the study reduced the clinical relapse of Crohn's disease in comparison with placebo by 50%. It is important to note that the patients in the study were in clinical remission for less than 24 months prior to entry, and presented laboratory evidence of inflammation. Patients of this type have about 75% greater risk of relapse in comparison with patients with long previous remission with normal laboratory tests.</p>
    <p>The results indicate that the fish oil capsules are the most effective and safe available treatment for preventing clinical relapses in Crohn's disease, with relatively few side effects.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 3______________________________________CLINICAL RESULTS AFTER 12 MONTHS OF TREATMENT       fish oil (n = 39)                   placebo (n = 39)______________________________________Withdrew      1             1REMISSIONS    23/38         10/38drop-out      4             1RELAPSES      15/38 (39,5%)*                       28/38 (73,7%)(intention to treat)with drop out         *chi square 9.05; p = 0.0026excluding drop-outs         11/34 = 32,4% 27/37 = 73,0%         *chi square 11,75; p = 0.0004______________________________________</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 4______________________________________23 PATIENTS GIVEN PUREPA IN REMISSIONAFTER 12 MONTHSTIME 0              12 MONTHS______________________________________ESR     37.8(6-122)SD 25                   19.5(3-40)SD 11.2(mm/h)p = 0.0002CRP     3.6(0.2-9.9)SD 3.4                   1.0(0.2-3.5)SD 0.9(mg/dl)p = 0.001ALFA-2  0.91(0.64-1.32)SD 0.15                   0.74(0.56-0.91)SD 0.1GLOBULIN(G/DL)p = 0.001ALFA-1  137(57-248)SD 49                   111(69-180)SD 33GLYCO-PROTEIN(mg/dl)p = 0.002ALBUMIN 3.7(3.0-4.4)SD 0.4                   4.0(3.1-4.7)SD 0.35(g/dl)p = 0.004WBC     8780(4000-11700)SD 2093                   7400(3310-11550)SD 2634p = 0.01______________________________________</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 5______________________________________PERCENTAGE OF MAIN FATTY ACIDS INCORPORATEDINTO RBCsPUREPA                 MIGLYOL            6                     6TIME 0           MONTHS    TIME 0      MONTHS______________________________________18:2n-6 10.2 Â±         7.0 Â±                6.4 Â± 0.4                        10.6 Â±                              9.8 Â±                                    11.1 Â± 1.5LA    1       0.8            1.5   220:4n-6 13.9 Â±         8.4 Â±                7.1 Â± 1.2                        13.5 Â±                              12.3 Â±                                    14.1 Â± 1.2AA    1.5     1.2            1.3   1.820:5n-3 0.2 Â±         4.1 Â±                5.8 Â± 0.6                        0.3 Â±                              0.1 Â±                                    0.2 Â± 0.1EPA   0.1     0.3            0.1   0.122:6m-3 2.9 Â±         7.4 Â±                11.4 Â± 1.2                        3.2 Â±                              2.8 Â±                                    3.0 Â± 0.6DHA   0.6     1.2            0.5   0.7______________________________________</pre>
    
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5252333">US5252333</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 28, 1989</td><td class="patent-data-table-td patent-date-value">Oct 12, 1993</td><td class="patent-data-table-td ">Scotia Holdings Plc</td><td class="patent-data-table-td ">Lithium salt-containing pharmaceutical compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5411988">US5411988</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 27, 1993</td><td class="patent-data-table-td patent-date-value">May 2, 1995</td><td class="patent-data-table-td ">Bockow; Barry I.</td><td class="patent-data-table-td ">Compositions and methods for inhibiting inflammation and adhesion formation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5422115">US5422115</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 20, 1992</td><td class="patent-data-table-td patent-date-value">Jun 6, 1995</td><td class="patent-data-table-td ">Efamol Holding Plc</td><td class="patent-data-table-td ">Methods of treatment and devices employing lithium salts</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5603953">US5603953</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 23, 1995</td><td class="patent-data-table-td patent-date-value">Feb 18, 1997</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Supported liquid membrane delivery devices</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0225303A1?cl=en">EP0225303A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 24, 1986</td><td class="patent-data-table-td patent-date-value">Jun 10, 1987</td><td class="patent-data-table-td ">ACO LÃ¤kemedel AB</td><td class="patent-data-table-td ">Use of a hydrophobic substance for the preparation of an enteric preparation for the treatment of obesity, and enteric preparation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0289204A2?cl=en">EP0289204A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 20, 1988</td><td class="patent-data-table-td patent-date-value">Nov 2, 1988</td><td class="patent-data-table-td ">Efamol Holdings Plc</td><td class="patent-data-table-td ">Lithium salt-containing pharmaceutical compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="http://www.google.com/url?id=EJdHBAABERAJ&amp;q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DGB%26NR%3D2223943A%26KC%3DA%26FT%3DD&amp;usg=AFQjCNHpC4J1Xpq0QMlBHe6_c0BEbM8ROg">GB2223943A</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Belluzzi, A., et al, abstract titled "<a href='http://scholar.google.com/scholar?q="New+Fish+Oil+Derivative+for+Preventing+Clinical+Relapses+in+Crohn%27s+Disease%3A+A+Double+Blind+Placebo+Controlled+Randomized+Trail"'>New Fish Oil Derivative for Preventing Clinical Relapses in Crohn's Disease: A Double Blind Placebo Controlled Randomized Trail</a>", published Digestive Disease Weekly 14 May 1995.</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Belluzzi, A., et al, abstract titled New Fish Oil Derivative for Preventing Clinical Relapses in Crohn s Disease: A Double Blind Placebo Controlled Randomized Trail , published Digestive Disease Weekly 14 May 1995.</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Rohm Pharma Gmbh brochure titled "<a href='http://scholar.google.com/scholar?q="Sustained-release+coatings+with+Eudragit%C2%AE+NE+30D+from+aqueous+dispersions"'>Sustained-release coatings with EudragitÂ® NE 30D from aqueous dispersions</a>" (1995).</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Rohm Pharma Gmbh brochure titled Sustained release coatings with Eudragit NE 30D from aqueous dispersions (1995).</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5948818">US5948818</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 30, 1998</td><td class="patent-data-table-td patent-date-value">Sep 7, 1999</td><td class="patent-data-table-td ">Tillotts Pharma Ag</td><td class="patent-data-table-td ">Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6166024">US6166024</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 12, 1999</td><td class="patent-data-table-td patent-date-value">Dec 26, 2000</td><td class="patent-data-table-td ">Mayo Foundation For Medical Education And Research</td><td class="patent-data-table-td ">Via formulations adapted for delayed-release oral or rectal administration</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6358939">US6358939</a></td><td class="patent-data-table-td patent-date-value">Dec 21, 1999</td><td class="patent-data-table-td patent-date-value">Mar 19, 2002</td><td class="patent-data-table-td ">Northern Lights Pharmaceuticals, Llc</td><td class="patent-data-table-td ">Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6432967">US6432967</a></td><td class="patent-data-table-td patent-date-value">Dec 21, 2000</td><td class="patent-data-table-td patent-date-value">Aug 13, 2002</td><td class="patent-data-table-td ">Mayo Foundation For Medical Education &amp; Research</td><td class="patent-data-table-td ">Enema and enterically-coated oral dosage forms of azathioprine</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6858595">US6858595</a></td><td class="patent-data-table-td patent-date-value">Dec 21, 2001</td><td class="patent-data-table-td patent-date-value">Feb 22, 2005</td><td class="patent-data-table-td ">Wisconsin Alumni Research Association</td><td class="patent-data-table-td ">Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6989377">US6989377</a></td><td class="patent-data-table-td patent-date-value">Jun 13, 2002</td><td class="patent-data-table-td patent-date-value">Jan 24, 2006</td><td class="patent-data-table-td ">Wisconsin Alumni Research Foundation</td><td class="patent-data-table-td ">Treating vitamin D responsive diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7678930">US7678930</a></td><td class="patent-data-table-td patent-date-value">Jul 11, 2003</td><td class="patent-data-table-td patent-date-value">Mar 16, 2010</td><td class="patent-data-table-td ">Pronova Biopharma Norge As</td><td class="patent-data-table-td ">Process for decreasing the amount of cholesterol in a marine oil using a volatile working fluid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7718698">US7718698</a></td><td class="patent-data-table-td patent-date-value">May 1, 2008</td><td class="patent-data-table-td patent-date-value">May 18, 2010</td><td class="patent-data-table-td ">Pronova Biopharma Norge As</td><td class="patent-data-table-td ">Adding fatty acid ester, a fatty acid amide, a free fatty acid or a hydrocarbon, to a mixture of a fat or an oil, being edible or for use in cosmetics; stripping and separating the environmental pollutant present in the fat or oil</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7732488">US7732488</a></td><td class="patent-data-table-td patent-date-value">Jul 8, 2003</td><td class="patent-data-table-td patent-date-value">Jun 8, 2010</td><td class="patent-data-table-td ">Pronova Biopharma Norge As</td><td class="patent-data-table-td ">Marine oil derived ethyl ester of eicosapentaenoic acid and docosahexaenoic acid, with specified reduced levels of brominated flame retardants; not a health supplement; treat hypertriglyceridaemia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8343753">US8343753</a></td><td class="patent-data-table-td patent-date-value">May 6, 2009</td><td class="patent-data-table-td patent-date-value">Jan 1, 2013</td><td class="patent-data-table-td ">Wake Forest University School Of Medicine</td><td class="patent-data-table-td ">Compositions, methods, and kits for polyunsaturated fatty acids from microalgae</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8383678">US8383678</a></td><td class="patent-data-table-td patent-date-value">Jan 5, 2011</td><td class="patent-data-table-td patent-date-value">Feb 26, 2013</td><td class="patent-data-table-td ">Chrysalis Pharma Ag</td><td class="patent-data-table-td ">Type a gelatin capsule containing PUFA in free acid form</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8481760">US8481760</a></td><td class="patent-data-table-td patent-date-value">Oct 13, 2009</td><td class="patent-data-table-td patent-date-value">Jul 9, 2013</td><td class="patent-data-table-td ">Northwestern University</td><td class="patent-data-table-td ">Inhibition and treatment of prostate cancer metastasis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8742141">US8742141</a></td><td class="patent-data-table-td patent-date-value">Jul 1, 2013</td><td class="patent-data-table-td patent-date-value">Jun 3, 2014</td><td class="patent-data-table-td ">Northwestern University</td><td class="patent-data-table-td ">Inhibition and treatment of prostate cancer metastasis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2002045681A2?cl=en">WO2002045681A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 5, 2001</td><td class="patent-data-table-td patent-date-value">Jun 13, 2002</td><td class="patent-data-table-td ">Sla Pharma Ag</td><td class="patent-data-table-td ">Solid polyunsaturated fatty acid compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2003019135A2?cl=en">WO2003019135A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 17, 2002</td><td class="patent-data-table-td patent-date-value">Mar 6, 2003</td><td class="patent-data-table-td ">Bio Rad Laboratories</td><td class="patent-data-table-td ">Reference control for high-sensitivity c-reactive protein testing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005070963A1?cl=en">WO2005070963A1</a></td><td class="patent-data-table-td patent-date-value">Jan 10, 2005</td><td class="patent-data-table-td patent-date-value">Aug 4, 2005</td><td class="patent-data-table-td ">Applied Molecular Evolution</td><td class="patent-data-table-td ">Fc region variants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005123060A1?cl=en">WO2005123060A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 15, 2005</td><td class="patent-data-table-td patent-date-value">Dec 29, 2005</td><td class="patent-data-table-td ">Ulrich Mittmann</td><td class="patent-data-table-td ">A pharmaceutical composition and its use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005123061A1?cl=en">WO2005123061A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 15, 2005</td><td class="patent-data-table-td patent-date-value">Dec 29, 2005</td><td class="patent-data-table-td ">Ulrich Mittmann</td><td class="patent-data-table-td ">Pharmaceutical compositions containing polyunsaturated fatty acid and at least one of an immunosuppressive agent or an antineoplastic agent</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=EJdHBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S560000">514/560</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=EJdHBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S963000">514/963</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=EJdHBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0009480000">A61K9/48</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=EJdHBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0001000000">A61P1/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=EJdHBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031202000">A61K31/202</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=EJdHBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047300000">A61K47/30</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=EJdHBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031000000">A61K31/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=EJdHBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031200000">A61K31/20</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=EJdHBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0001040000">A61P1/04</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=EJdHBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=Y10S514/963">Y10S514/963</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=EJdHBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/202">A61K31/202</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=EJdHBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K9/4891">A61K9/4891</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">A61K9/48Z</span>, <span class="nested-value">A61K31/202</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Feb 18, 2014</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CLAIMS 10 AND 13-17 ARE CANCELLED.CLAIMS 1-9, 11 AND 12 ARE DETERMINED TO BE PATENTABLE AS AMENDED.NEW CLAIMS 18-33 ARE ADDED AND DETERMINED TO BE PATENTABLE.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">May 14, 2013</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20130403</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 28, 2012</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">MEDEVA PHARMA SUISSE SA, SWITZERLAND</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:MEDEVA PHARMA SCHWEIZ AG;REEL/FRAME:029371/0782</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20011214</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDEVA PHARMA SUISSE SA;REEL/FRAME:029363/0414</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">CHRYSALIS PHARMA AG, SWITZERLAND</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20120821</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">19990428</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:TILLOTTS PHARMA AG;REEL/FRAME:029363/0320</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">MEDEVA PHARMA SCHWEIZ AG, SWITZERLAND</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 14, 2010</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">12</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jan 20, 2006</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 27, 2001</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 1, 1998</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">TILLOTTS PHARMA AG, SWITZERLAND</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BUSER, THOMAS;CAMPORESI, EMILIO P.;REEL/FRAME:009243/0054;SIGNING DATES FROM 19980318 TO 19980528</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_4ff636b3d23669b7103f3b3a3a18b4cd.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U1JehKgac72ZRiXmPuD_gLx5TrN2w\u0026id=EJdHBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U1bybqU9S8f4c6itophFCn6wR1tvg\u0026id=EJdHBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U21wA7sBaVyRX4_6W0EV5_Z4MtKBw","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Treatment_of_inflammatory_bowel_disease.pdf?id=EJdHBAABERAJ\u0026output=pdf\u0026sig=ACfU3U1VI4GKy3Mca9q-OmG3wb9S7wHEAg"},"sample_url":"http://www.google.com/patents/reader?id=EJdHBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>